Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen

Key Points

• Supernus Pharmaceuticals has been upgraded to a "buy" rating by Wall Street Zen, moving from a previous "hold" rating in a research report issued on Saturday.
• Cantor Fitzgerald also upgraded the company, lifting its rating from "neutral" to "overweight" with a target price set at $42.00.
• Supernus Pharmaceuticals has seen recent institutional investments, with some institutions significantly increasing their stakes in the company during the first quarter of 2023.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

Separately, Cantor Fitzgerald upgraded Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price target for the company in a research note on Wednesday.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN traded up $0.41 during trading hours on Friday, reaching $35.51. 858,699 shares of the company were exchanged, compared to its average volume of 798,286. The company has a market capitalization of $1.99 billion, a P/E ratio of 31.99 and a beta of 0.74. Supernus Pharmaceuticals has a 1-year low of $27.05 and a 1-year high of $40.28. The business has a 50 day moving average of $32.64 and a 200 day moving average of $33.34.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after buying an additional 1,083 shares during the period. Two Sigma Advisers LP boosted its stake in Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after purchasing an additional 1,000 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Supernus Pharmaceuticals by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after buying an additional 9,590 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after buying an additional 3,495 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after buying an additional 6,867 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.